drug use flow chartsdformulary.h.usm.my/assets/flow_chart_2020v9nov... · 3 | p a g e flow chart...

0 | P a g e

COMPILED BY:

UNIT FARMASI

KLINIKAL DAN

MAKLUMAT DRUG

HOSPITAL USM Drug Use Flow Charts

2020

1 | P a g e

Contents GUIDELINES FOR USING PROTON PUMP INHIBITOR (PPI) HUSM....................1

FLOW CHART USAGE OF PPI IN HUSM ...................................................................3

LIPID LOWERING THERAPY USM GUIDELINES ......................................................5

INDICATION OF USING AMLODIPINE (AND FELODIPINE) IN HUSM

(SUGGESTION) ................................................................................................................9 PROPOSAL GUIDELINES ON PLAVIX PRESCRIPTION FOR CARDIOLOGY

PATIENTS HUSM ..........................................................................................................15

SIMPLIFIED NOVOSEVEN PROTOCOL FOR HAEMATOLOGY USM ................16

SIMPLIFIED NOVOSEVEN PROTOCOL FOR NEUROSURGERY USM ...............17 GUIDELINE FOR OFF-LABEL USE OF RECOMBINANT ACTIVATED FACTOR

VII (rFVIIa) ......................................................................................................................18 GUIDELINE FOR THE USE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN NON-HEMOPHILIC PATIENTS WITH LIFE-THREATENING

HEMORRHAGE .............................................................................................................20 GUIDELINES FOR OUTPATIENT TREATMENT OF CHRONIC ASTHMA

DEPARTMENT OF MEDICINE HOSPITAL USM......................................................29

GUIDELINES FOR USING INFLUENZA VACCINE .................................................32 FLOW CHART PENGGUNAAN DRUG UNTUK RAWATAN ATTENTION

DEFICIT HYPERACTIVITY DISORDER (ADHD) ......................................................33

ALGORITHM FOR MEDICATIONS OF SCHIZOPHRENIA ....................................35

ACUTE TREATMENT OF MANIA ..............................................................................37

ACUTE TREATMENT OF BIPOLAR DEPRESSION .................................................38 PSYCOPHARMACOLOGICAL TREATMENT ALGORITHM FOR

GENERALUIZED ANXIETY DISORDER (GAD) .......................................................39 ALGORITHM (2) FOR THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE

DISORDER (MDD) ........................................................................................................40

ALGORITHM FOR MANAGEMENT OF DEMENTIA .............................................41

ALZHEIMER’S DISEASE TREATMENT STRATEGY .................................................42

PARKINSON DISEASE .................................................................................................43 FLOW CHART FOR TREATMENT HEPATITIS B IN TREATMENT NAÏVE

PATIENTS .......................................................................................................................44

FLOW CHART OF CHRONIC VIRAL HEPATITIS B PRE CORE MUTANT

HBEAG NEGATIVE ......................................................................................................45

FLOW CHART FOR GENITAL ULCER SYNDROME ...............................................46

TREATMENT FOR SYPHILIS AND CHANCROID ....................................................46

FLOW CHART FOR VAGINAL DISCHARGE SYNDROME ...................................47

FLOW CHART FOR URETHRAL DISCHARGE SYNDROME IN MEN .................48

OUTPATIENT TREATMENT OF CAP ........................................................................49

FLOW CHART OF USING SULPERAZONE IN ICU ................................................51 GUIDELINES FOR USING NOVOMIX 30 FLEXPEN HOSPITAL UNIVERSITI

SAINS MALAYSIA .........................................................................................................52

FLOWCHART FOR USE OF GLUCOPHAGE XR .....................................................53

FLOWCHART FOR USE OF INSULIN DETEMIR .....................................................54 ALGORITHM FOR THE MANAGEMENT OF POSTMENOPAUSAL

OSTEOPOROSIS ............................................................................................................55

ZOLENDRONIC ACID PRESCRIPTION FLOW CHART .........................................56

2 | P a g e

FLOW CHART FOR USING IMATINIB IN CHRONIC MYELOID LEUKEMIA

(CML), PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ....................................56

ARCOXIA PRESCRIPTION FLOW CHART ...............................................................58

OUTPATIENT PAIN PRESCRIPTION FLOW CHART .............................................59 FLOWCHART OF PATIENTS DIAGNOSED WITH BACTERIAL

CONJUNCTIVITIS .........................................................................................................60

FLOWCHART OF PATIENTS DIAGNOSED WITH BACTERIAL KERATITIS .....61 FLOWCHART OF PATIENTS REQUIRING PRE AND POST CATARACT

SURGERY ANTIBIOTIC PROPHYLAXIS ....................................................................62

FLOW CHART FOR USING OLOPATADINE 0.1% ................................................63

TREATMENT ALGORITHM OF ALLERGIC RHINITIS (AR) ...................................64

FLOW CHART OF THALASSAEMIA PATIENT WITH IRON OVERLOAD ........65

INTERFERON BETA-1B FLOWCHART .....................................................................66

GUIDELINE OF PAIN MANAGEMENT ....................................................................67 GUIDELINE ON THE USE OF GLUCOSAMINE FOR OSTEOARTHRITIS PATIENT FOR USM STAFF (13TH MARCH 2018) PROF DR ABDUL RAZAK

SULAIMAN .....................................................................................................................70

HOSPITAL UNIVERSITI SAINS MALAYSIA NOACS USAGE FLOW CHART .....72

TICAGRELOR USAGE FLOW CHART .......................................................................73

FLOW CHART FOR INSULIN AT KRK ......................................................................74 ALGORITHM/DIAGRAM: HA +/- PRP USAGE GUIDELINES FOR KNEE OA IN

HOSPITAL USM .............................................................................................................76 CARTA ALIR PROSES KERJA BARU BEKALAN UBAT STANDARD

TERKAWAL / NON-STANDARD KUOTA KEPADA PESAKIT .............................77

PROTOCOL FOR MALIGNANT HYPERTHERMIA (MH) .......................................78

2020 HOSPITAL USM GUIDELINE FOR VIRAL HBV THERAPY .........................79

1 | P a g e

GUIDELINES FOR USING PROTON PUMP INHIBITOR (PPI) HUSM

Upper GIT bleed

Mucosal break lesion

Treatment Prophylatic / suspected

Upper GIT bleed confirm on OGDS Tab / IV PPI 40 mg OD

Chronic

T. PPI 40mg OD x 3-6/12

Long term – if has other risk factors eg:

- Age > 65 years - On anti-platelet / NSAIDs /

STEROIDs

Acute

IV PPI 80 mg stat

Emergency OGDS within 24 hour

If not properly heal

IV PPI 8mg/hr x 72 hours

2 | P a g e

Maintenance T. PPI 40 mg BD x 4-6/52 therapy

If symptom persisted

Maintenance T. PPI OD x 3-6/12

Remarks:

1st line Pantoprazole

2nd line Esomeprazole

3 | P a g e

FLOW CHART USAGE OF PPI IN HUSM ENDOSCOPY MEETING ON 7/2/12

Bleeding cases (Non variceal bleed)

1st Endoscopic procedure, then

2nd Proton pump inhibitor (PPI), then 3rd Mucosal protective therapy (oral sucralfate), then

4th Surgival intervention

Bleeding cases (variceal bleed)

1st line I/V Octreotide 25-50mcg, then 25-50mcg/hr Or

Somatostatin 250mcg stat then 250mcg/hr 2nd line PPI infusion

PPI

1st line I/V PPI 80 mg stat, then

I/V PPI 8 mg/hr for 3 – 5/7, then I/V PPI 40 mg BD

Follow-up by tab.PPI 40 mg BD x 8 – 12/52 and to repeat endoscopy if

rebleed or after complete treatment.

Mucosal break lesion (Prophylaxis)

1st line I/V Pantoprazole 40mg stat 2nd line I/V Esomeprazole 40 mg BD

3rd line Oral Sucralfate 4th line I/V Ranitidine or tablet

Peptic Ulser disease (PUD)

1st line Tab. Pantoprazole 40mg OD/BD, then

2nd line Tab. Esomeprazole 40 mg OD/BD, then 3rd line Tab. Omeprazole 20 mg BD

4 | P a g e

In cases of PUD (No. OGDS) (No. PPI test)

Tab. Ganaton 50 mg BD/TDS with

1st line Tab. Pantoprazole 40 mg OD/BD

2nd line Tab. Esomeprazole 40 mg OD/BD

If not improve after 2/52 refer results endoscopy investigation (Gastro/Surgical)

In cases of no OGDS for PPI test

1st line Tab. Pantoprazole 40 mg BD x 2/52 then decision OR

2nd line Tab. Esomeprazole 40 mg BD x 2/52 then decision.

In Cases of Biliary gastritis/ recurrent GERD/ GERD (Gastrooesophageal disease)

1) T. Ganaton 50 mg BD/TDS with 1st line

T. Esomeprazole 40 mg BD/TDS

2) T. Ganaton 50 mg BD/TDS with 2 nd line T. Pantoprazole 40 mg BD

In Cases of PUD with normal OGDS/ NERD (non erosive gastritis)

T. Ganaton 50 mg BD/TDS WITH

1st line Tab. Esomeprazole 40 mg OD/BD

2 nd line Tab. Pantoprazole 40 mg OD/BD

Last Update: February 2012

5 | P a g e

LIPID LOWERING THERAPY USM GUIDELINES

Indications for use

1. Coronary heart disease (CHD) 2. CHD disease equivalent

a) Diabetes Mellitus b) Carotid artery disease

c) Peripheral artery disease d) Abdominal aortic aneurysm

3. Familial hyperlipidaemia (or total chol > 8, LDL chol > 6) 4. CHD high risk individuals

a) Individuals with 2 or more risk factors 5. CHD low risk

a) Individuals with less than 2 risk factors 6. If asymptomatic but total cholesterol ≥ 5.0 mmol/l, LDL cholesterol

≥ 3.0 mmol/l and total CVD risk of projected CVD risk at 60 years of age is ≥ 5%.

7. Others a) Individuals with chronic renal disease (Creatinine > 133

umol/L or GFR < 60 ml/min/1.73 m2) b) Metabolic syndrome

Drug Dose range ( mg )

LDL reduction Cost for 1/12 rx RM

Pravastatin 10 - 40 19 – 40 %

Simvastatin 10 - 80 28 - 48 %

Lovastatin 20 - 80 29 – 48 %

Atorvastatin 10 - 80 38 – 54 %

Rosuvastatin 10 - 40 52 – 63 %

Indications 1-4

• Aggressive lipid lowering therapy required

• High dose and high potency drug required

• Suggestion

1. Coronary heart disease (CHD) 2. CHD disease equivalent

i) Diabetes Mellitus ii) Carotid artery disease iii) Peripheral artery disease iv) Abdominal aortic aneurysm

3. Familial hyperlipidaemia (or total chol > 8, LDL, chol >6) 4. CHD high risk individuals- Individuals with 2 or more

6 | P a g e

Check FLP

Start atorvastatin

10 – 20 mg od

Check FLP after

3/12

TLC

Total C > 4.5 or

LDL > 2.5

Total C < 4.5 or

LDL < 2.5

Intensification of Rx

Increase dose of

Atovarstatin or change

to Rosuvastatin

Continue medication or

consider de-escalation of Rx

ie change to Simvastatin or

Pravastatin as per indicated

TLC

TLC = Therapeutic lifestyle changes

7 | P a g e

Indications 5-7:

• Lipid lowering therapy can be step wise intensification

• Suggestions

1. CHD low risk

a) Individuals with less than 2 risk factors

2. If asymptomatic but total cholesterol ≥ 5.0 mmol/l, LDL cholesterol ≥ 3.0

mmol/l and total CVD risk of projected CVD risk at 60 years of age is ≥ 5 %.

3. Others

a) Individuals with chronic renal disease

(Creatinine > 1.33 umol/L or GFR < 60 ml/min/1.73 m2)

b) Metabolic syndrome

Total chol

Risk score: 10 year risk for CV death

Total risk 5.0

LDL chol > 3.0

Continue TLC Continue TLC

Reassess risk yearly

Start drug

therapy If risk ≥ 5 % and

Total chol < 4.5 and

LDL chol < 2.5

TLC = Therapeutic

lifestyle changes

Consider drug

therapy

8 | P a g e

Prepared by Dr Tee Meng Hun & AP Dr Zulkurnai Yusof, Med Dept

Drug therapy indicated

Total chol 5.0 – 5.9

LDL chol 2.5 – 3.5

Total chol 6.0 – 6.9

LDL chol 3.5- 4.5

Total chol 7.0

LDL chol 4.5

Pravastatin or

simvastatin

Simvastatin or

atorvastatin

Atorvatatin or

rosuvastatin

If targets not achieved : Total chol > 4.5 or LDL > 2.5

CHECK COMPLIANCE TO TLC AND DRUG THERAPY

Consider intensifying treatment

Simvastatin

Ezetimide

Or

Atorvastatin

Or

Rosuvastatin

Combination therapy

Atorvastatin

Or

Rosuvastatin

And or

Ezetimibe

And or

Fibrates etc

9 | P a g e

INDICATION OF USING AMLODIPINE (AND FELODIPINE) IN HUSM (SUGGESTION)

1. Introduction

Calcium channel blockers work by blocking the initial calcium influx into myocytes and vascular smooth muscle cells. Amlodipine and felodipine are long acting second generation dihydropyridine that have vascular smooth muscle relaxing activity with no or minimal negative inotropic

effects. They have a greater selectivity for vascular smooth muscle compared to the myocardium. They vasodilate coronary arteries reduce coronary resistance, increase coronary blood flow and may enhance the

development of coronary collaterals.

2.Indication of using calcium channel blocker (CCB)

2a. The use of CCB as anti-ischemic agent

-calcium channel blocker has been shown to exert anti-angina properties in various ways such as reduction in heart rate, reduction in contractility,

reduction in afterload and direct vasodilatation. -calcium channel blocker should be considered if there are

contraindications or adverse reactions to either beta blockers of nitrates or if symptoms are not well controlled with a combination of these

agents.

2b.The use in acute coronary syndrome (ACS) patients.

- The potential benefits of either amlodipine or felodipine in acute MI has not been examined directly.

- Amlodipine is often used in patients with acute MI when hypertension is not adequately controlled by other therapy of proven

benefit (beta blockers and ACE inhibitors ).

- Study in stable coronary heart disease (PREVENT trial) found no or little benefit of amlodipine but also has no harm.

- Therefore amlodipine is not indicated as first line therapy on ACS patients unlike ACE inhibitors and beta blockers.

2c. The use of CCB in patients with heart failure

- The potential benefit of either amlodipine or felodipine in acute MI has not been examined directly. However, clinical trial that have

evaluated these drugs in heart failure (V- HeFT III and the PRAISE trials) found no or little benefit but also no harm.

- In patient with heart failure, amlodipine in at a drug choice as compared to ACE inhibitors, beta blockers and aldosterone antagonist.

10 | P a g e

2d.The use of CCB in hypertension patients.

- Although recommendations for initiating medical therapy in essential hypertension have been proposed, there is no uniform

agreement on which antihypertensive agent should be given as initial therapy. A variety of different classes of drugs can be used in this setting.

These include the thiazide diuretics, beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers and calcium

channel blockers.

- There have been limited data as to whether different antihypertensive drugs have variable effects upon patient outcomes,

particularly cardiovascular morbidity and mortality. However, an increasing number of trials have provided evidence that at the same level of blood pressure control, most antihypertensive drugs provide the same

degree of cardiovascular protection provided there are no other compelling indications.

- The choice of drug should be based on the patient’s individual risk profile and the tolerability of the drugs.

- “First-line” drugs should have the following properties : 1. reduce long-term morbidity and mortality 2. high efficacy of once-daily administration

3. no adverse effects on concomitant risk factor 4. good tolerability

- based on JNC VII guidelines, hypertensive naïve patient should receive diuretics as first line drug.

2e. The use of CCB in anti-arrythmic agents

-the use of amlodipine as anti- arrythmic agents therapy was not well

studied unlike verapamil and diltiazem, therefore it is not recommended as anti-arrythmic therapy.

2f. The use of CCB in patients with renal disease/nephropathy

- Hypertension is common in chronic renal disease and is risk factor for progression of renal damage, and reduction of blood pressure (BP) is

an efficient way of preventing or slowing the progression of this damage. BP – lowering effects are common to all antihypertensive drugs, but intra-renal effects differ between classes and between individual drugs within

certain classes. Angiotensin – converting enzyme (ACE) inhibitors and angiotensin receptors blockers (ARB) have beneficial effects on

proteinuria and declining renal function that appear to be mediated by factors additional to their effects on BP. These RAS inhibitors are

recommended as first-line antihypertensive approach in patients with chronic kidney disease.

- Calcium channel antagonist are highly a heterogenous class of compounds, and it appears that some agents are more suitable for use in

patients with chronic renal disease than others. Most common calcium channel blockers are nondihydropyridine group like verapamil and

diltiazem.

11 | P a g e

- Dihydropyridine calcium channel blockers (eg nifedipine and amlodipine) may worsen proteinuria and accelerate the progression of

disease in patients with nondiabetic or diabetic nephropathy. 2g. The use of CCB in peripheral vascular disease (PVD) patient.

- Unlike verapamil, the use of amlodipine and felodipine in treating peripheral vascular disease patients are not well studied. Therefore,

it is not recommended to use these drugs to treat PVD patients.

2h. The use of CCB in Pulmonary Artery Hypertension patients.

- The oral vasodilators of choice are the calcium channel blockers nifedipine and diltiazem. Verapamil is not recommended, since it

tends to posses significant negative inotropic properties.

- Amlodipine has been a useful alternative for patients who are intolerant of the other agents (eg. Because of edema, bradycardia,

tachycardia, or hypotension)

- The use of Felodipine in pulmonary artery hypertension is not well studied.

3. Advantages of Amlodipine (and felodipine) above other antihypertensive.

3a.Single daily dose, therefore this will improve patient compliance.

3b. No need for renal function monitoring. 3c. Among the least side effects compared to other anti-hypertensive.

3d. In comparison between amlodipine and felodipine, on of the retrospective study has shown that amlodipine has better patient’s

adherence compared to felodipine.

4. Disadvantages of CCB above other antihypertensive.

4a. The potential benefit of either amlodipine or felodipine in ACS has not been examined directly in ACS patients. A systematic analysis of all

randomized calcium blocker trials in unstable angina suggests calcium channel blockers that as a class do not prevent the development of acute myocardial infarction or reduce mortality, and it also has no harm to these

group of patients. 4b. Short-acting CCB (i.e. Nifedipine) has a relatively high incidence of adverse side effects, including peripheral edema (not related to heart

failure), flushing, headaches, and lightheadedness, which is due to peripheral vasodilatation.

4c. There was a study (cross sectional) showed that there was a higher rate of depression among hypertensive patients who were on calcium

channel blocker as compared to other anti-hypertensive. 4d. Both amlodipine and felodipine are long acting calcium channel

blockers, therefore it is not recommended as first line therapy for hypertensive urgency.

12 | P a g e

List of Tables

Table 1 Comparative pharmacokinetics of selected dihydropyridine

calcium channel antagonists

Nifedipine Nisoldipine Felodipine Amlodipine Diodipine

Oral absorption

>90 >90 >90 >90 >90

Oral bioavailability

30-50 5-15 10-25 60-65 5-15

Elimination half-life

3-5 4-10 2-8 35-50 3-15

Table-Dosing and costs of the Calcium Channel Blockers

Drug Initial Dose

Usual Dosage Range

Cost x 30 days

Verapamil

- regular (Isoptia® generic)

- long acting (Isoptin SR®) (Varelan®)

80mg TID

180 mg daily

180 mg daily

80-160 mg TID 120 mg daily-

240mg BID 120-480 mg daily

$37.33-$68.15 $37.52-$99.94 $32.87-$85.92

Diltiazem

- regular (Cardizem® generic)

- long acting (Cardizem SR®)**

(Cardizem CD®)

30mg TID 60 mg BID

120 mg daily

30mg TID-90 mg

QID 60-80 mg BID

120 mg-300mg daily

$28.51- $83.61

$51.63- $126.31**

$47.12- $95.89

Felodipine (Plendil®, Renedil®) Nifedipine

- regular capsules (Adalat®generic)

- long acting (Adalat PA®)**

(Adalt XL®) Amlodipine (Norvasc®) Nicardipine (Cardene®)

5mg daily

10mg TID 10 mg BID

30 mg daily

5 mg daily 10mg TID

2.5-20 mg daily

10mg TID-30 mg QID

10-40mg BID 30-120 mg daily

5-10 mg daily 20-40 mg TID

$23.13-$83.61

$27.25-$89.52 $37.90-

$104.72** $37.81-$104.72 $46.14-$65.34

$62.04-$117.58

**Base on wholesale acquisition cost Feb. 1995 of least expensive product and professional fee of $6.50 as April 1, 1995. Pharmcare no longer covers Cardizem

SR and Adalat PA

13 | P a g e

5. References

1. Antiischemic Agents in the Management of Unstable Angina and Acute Non-ST Elevation (Non-Q Wave) Myocardial Infarction.

Michael Simons, MD. Up to date version 13.3

2. Calcium Channel Blockers in Acute Myocardial Infarction. Robert S Rosenson, MD Harold L Keneddy, MD, MPH. Up to date version

13.3.

3. Calcium Channel Blockers in the Management of Stable Angina Pectoris. Joseph P. Kannam, MD. Julian M Aroesty, MD. Bernard J

Gersh, MB, ChB, DPhil, FRCP. UpToDate version 13.3.

4. Choice of Therapy in Essential Hypertension: Clinical Trials. Norman M Kaplan, MD, Burton D Rose, MD. UpToDate version 13.3.

5. Wenzel, Rene R. Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy. (Review). Dugs. 65 (Suppl

2):29-39, 2005.

6. JNC VII guidelines.

7. Medical Management of Claudication. UpToDate version 13.3.

8. Non Diabetic Kidney Disease (Andrew S) N Engl J Med. VOl 347. No 19. November 7, 2002.

9. Nephropathy in Patient with Type 2 Diabetes. Remuzzi et al. N Engl

J Med. Vol. 346, No. 15 April 11, 2002.

10. Adherence to Calcium Channel Blocker Therapy in Older Adults: A Comparison of Amlodipine and Felodipine. Menzin J et al. J Int Med

Res. 2004 May-June; 32(3) :233-9.

14 | P a g e

FLOW CHART

Diagnosis of hypertension

Initiate lifestyle modification

If still not achieve BP target (100mmHg) –

consider 2 drugs

Use appropriate

anti-hypertensive

agent

15 | P a g e

PROPOSAL GUIDELINES ON PLAVIX PRESCRIPTION FOR CARDIOLOGY PATIENTS HUSM

ACUTE CORONARY SYNDROME

PERCUTANEOUS CORONARY

INTERVENTION (PCI)

INTRACEPT ASD CLOSURE

DEVICE

CABG

• NSTEMI/UA = 9 months

• STEMI = 8 days

• Bare metal stent = 3-4

weeks

• Drug eluting

stent (DES) = 6-12

months

• Plavix x 3

months

• No indication

* Contraindication for aspirin, ticlopidine is a substitution

16 | P a g e

SIMPLIFIED NOVOSEVEN PROTOCOL FOR HAEMATOLOGY USM

FLOW CHART

1. HAEMOPHILIA A OR B WITH INHIBITOR 2. CONGENITAL FACTOR VII DEFICIENCY

3. GLANZMANN’S THROMBASTHENIA 4. AN INHERITED PLATELET FUNCTION DISORDER

(ANY OTHER HAEMOTOLOGICAL CONDITIONS: SEE OFF-LABEL USE PROTOCOL FOR NOVOSEVEN)

IN SEVERE DIVC OR COAGULOPATHY AND THREATEN LIFE OF THE PATIENT

GIVE NOVOSEVEN (THE DOSAGE: HAEMATOLOGIST’S DECISION)

DIVC OR COAGULOPATHY CORRECTED

Last update: 24 JANUARY 2012

17 | P a g e

SIMPLIFIED NOVOSEVEN PROTOCOL FOR NEUROSURGERY USM

FLOW CHART

(POLY)TRAUMA PATIENT

IN SEVERE DIVC OR COAGULOPATHY. AND FOR URGENT/EMERGENCY LIFE-SAVING

SURGERY

GIVE NOVOSEVEN

(GENERALLY THE DOSAGE: 1-3 AMPOULES

DEPENDS ON: SEVERITY AND PATIENT’S BODY WEIGHT)

DIVC CORRECTED

SURGERY

Last update: 24 JANUARY 2012

18 | P a g e

GUIDELINE FOR OFF-LABEL USE OF RECOMBINANT ACTIVATED FACTOR VII (rFVIIa)

Jan 2010 Malaysian Society of Haematology

Algorithm for use of rFVIIa

Control of bleeding source with surgery or embolisation

Massive

Haemorrhage

- Control of bleeding source with surgery or embolisation - Blood components therapy

- Reversal of any anticoagulation

[PPH: Uterine massage/compression, uterotonic agents]

Attempt to correct:

Hct to > 24%

Fibrinogen > 0.5-1.0g/L

Platelets > 50 x 109/L

pH ≥ 7.2

Bleeding

Stopped

- Consider rFVIIa - Discuss with on-call Consultant in-charge - Fill up registry form for off-label use of

rFVIIa

Administer rFVIIa (Single bolus over 3-5mins – Dose as per

institution practice)

Persistent bleeding & generalized oozing

despite surgical control

Re-administer rFVIIa

[PPH: Consider hysterectomy if

bleeding persists after 2 doses of

rFVIIa]

Consider after 30-60mins



Attempt to correct:

Hct to > 24%



pH ≥ 7.2

Bleeding

Stopped

Guideline for the use of rFVIIa

1. Use of rFVIIa in non-haemophilic patients and any decision to use

rFVIIa rests exclusively with the

prescribing clinicians.

2. Appropriate medical and surgical interventions should be carried out to

reduce the magnitude of critical

bleeding before initiating

administration of rFVIIa.

3. RFVIIa should only be used where the clinician considers the benefit

outweighs the risk of thrombosis.

4. The algorithm provided here serves as a guide only. Adherence to this

guideline is encourage but not

mandatory.

5. Following administration of rFVIIa, all patients should be monitored for

signs of improvement and adverse

events.

6. The prescribing clinican should report all off-label use of rFVIIa to the

rFVIIa Registry in Managing

Critical Bleeds in Non-Haemophilia

Patients through completion of the

relevant data collection form.

19 | P a g e

GUIDELINE FOR OFF-LABEL USE OF RECOMBINANT ACTIVATED FACTOR VII (rFVIIa)

Malaysian Society of Haematology

(Member in USM preparing this new protocol: AP Dr

Zamzuri Idris; Neurosains)

Jan 2010

20 | P a g e

GUIDELINE FOR THE USE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN NON-HEMOPHILIC PATIENTS WITH LIFE-THREATENING

HEMORRHAGE

Introduction

Recombinant FVIIa (Novoseven) was developed for the treatment of bleeding in patients with hemophilia who have inhibitors against factor

VIII or IX. It is manufactured by recombinant technology using baby hamster kidneys.1

Licensed indications 2

It is currently licensed for the treatment of bleeding episodes and for controlling bleeding during surgery in the following conditions:

5. Inherited or acquired hemophilia with inhibitors 6. Congenital factor VII deficiency and

7. Glanzmann’s thrombasthenia, an inherited platelet function disorder

Out-of license or off-label use There is a growing trend for out-of license use of rFVIIa in non-hemophilic

patients with life-threatening or massive hemorrhage* such as from trauma, surgery, post-partum, liver transplant/ failure and intracerebral

hemorrhage.

Definition of massive hemorrhage* 3 ▪ replacement of total blood volume within 24 hours (>10 units of

packed red cell in a 70kg patient) ▪ loss of 50% of circulating blood volume in 3 hours or

▪ loss of 150 ml of blood per minute

Mode of action Administration of pharmacologic doses of exogenous rFVIIa directly

enhances thrombin generation on the platelet surface at the site of injury independently of factor VIII or IX resulting in a stable fibrin clot.

Recombinant FVIIa has a short half-life of 2.5 hours.1,4,5

Recommended dose

The recommended dose of rFVIIa for hemophilia with inhibitors is 90 to 120 ug/kg by slow iv bolus over 2 to 5 minutes. The optimal dosing for off-label use is not known. A second dose can be repeated after 1 to 2 hours if

bleeding is still not controlled.1,4

* Note that inhibitors in hemophilia patients render factor VIII/ IX concentrates or

plasma useless by neutralizing the coagulation factors VIII or IX. The recommended dose of 90 to 120 ug/kg is the amount of rFVIIa required to

generate enough thrombin to form a tight fibrin clot in these patients. This dose cannot be extrapolated to patients with life-threatening bleeding with otherwise normal coagulation or in whom any abnormal coagulation can be corrected with

plasma. Furthermore tissue injury following trauma, surgery or post-partum

21 | P a g e

releases tissue factor which activates the coagulation system; hence by giving the recommended dose of rFVIIa (for inhibitor patients) for life-threatening

hemorrhage in these patients may result in thrombotic complications. Smaller doses between 30 to 60 ug/kg have been used with good response in these

situations.6,7

Contraindications 3

Absolute ▪ Unsalvageable patients

▪ Allergy to mouse, hamster or bovine proteins

Relative ▪ Known thrombophilia

▪ History of recent thromboembolic events within the last 6 months eg. myocardial infarction, stroke or deep vein thrombosis

Precautions 3

▪ Patients with prosthetic heart valve ▪ Patients with recent coronary angioplasty and stent insertion

▪ Patients with coronary artery disease ▪ Patients with cerebrovascular disease

▪ Patients on ECMO or VAD ▪ Patients with disseminated intravascular coagulation or sepsis

Preconditions before rFVIIa administration 3

▪ Appropriate surgical interventions to secure hemostasis have been carried out if indicated

▪ Appropriate blood component therapy has been instituted in abnormal coagulation states to attempt to achieve a fibrinogen level

>1 g/L and platelet count >50 x109/L ▪ Attempt to correct anaemia to keep Hb >7 g/dL or Hct >24% with

blood transfusion ▪ Keep pH ≥ 7.2

▪ Core temperature ≥ 34°C ▪ Normal serum calcium

Timing and appropriateness of administration

For best outcome, consider rFVIIa early after the first blood component replacement fails to control the hemorrhage or after failing appropriate

surgical intervention. Do not use in non-salvageable patients or if the overall outlook of the patient is so poor that arresting the hemorrhage

does not alter the outcome.3

Monitoring

There is no specific laboratory test to monitor the efficacy of rFVIIa. The clinical response of cessation of bleeding, the amount of blood loss and

transfusion requirement are monitored and recorded.1,4

22 | P a g e

Complications There is a continuing concern that rFVIIa can cause thromboembolic

complications because it is an activated factor given in doses to cause a non-physiological rise in factor VII levels by more than 1000-fold. In

hemophilia with inhibitors there is a 1% incidence of thromboembolic events eg. myocardial infarction, ischemic stroke, deep vein thrombosis or

pulmonary embolism.5 Similar events have been reported in non-hemophilic patients but the true incidence is not known. Hence,

administration of rFVIIa should be used with caution in patients who have a predisposition to thrombosis such as diabetes mellitus, cardiovascular

disease, cancer, obesity and the elderly.4,6

Specific situations

Disseminated intravascular coagulation A literature review found 15 uncontrolled studies with 32 cases on the use

of rFVIIa for disseminated intravascular coagulation due to postpartum hemorrhage. A single dose of rFVIIa was able to control bleeding in 80% of

patients with a median dose of 67.6 ug/kg (range 30-120 ug/kg). In another series of 18 patients with DIC associated with metastatic cancer, 80% of patients responded to a median of 5 doses of rFVIIa at 90 ug/kg

with no thromboembolic complications. 7, 8

Intracerebral hemorrhage

Following an intracerebral hemorrhage, evidence shows that there is expansion of the hematoma mass in 50% of patients for up to 6 hours. This suggests that early arrest of hematoma growth would improve outcome. In

a double-blind, placebo-controlled trial of 399 patients with intracerebral hemorrhage diagnosed within 3 hours of onset by CT scan, patients were randomly included to receive placebo or rFVIIa at doses of 40 ug/kg, 80

ug/kg or 160 ug/kg. Treatment with rFVIIa was found to limit the growth of the hematoma, reduce mortality by 35% and improve functional

outcome at 90 days in all 3 dosing groups but with an increase frequency of thromboembolic events with the highest dose. Best outcomes are seen

in patients treated early with a Glasgow Coma Scale of ≥13.9,10

This study was followed by a larger phase III randomized, multicenter, double-blind, placebo-controlled trial to confirm the above findings. Eight

hundred and forty one patients with inracerebral hemorrhage were randomized to receive placebo or rFVIIa at doses of 20 ug/kg or 80 ug/kg within 4 hours after the onset of stroke. The hemostatic effect was similar

but there was no difference in severe disability or mortality at 90 days between the placebo and rFVIIa treatment arms.11

Liver transplant/ failure

There have been anecdotal reports of the successful use of rFVIIa in controlling bleeding in patients with liver disease but failures and recurrent

23 | P a g e

bleeding have also been reported. Recombinant FVIIa has been successfully used in controlling bleeding in liver transplant in non-cirrhotic

patients.6,12,13

Postpartum hemorrhage (PPH) There are no randomized studies, only case series of the use of rFVIIa in PPH reporting good response with cessation of bleeding in > 80% at a mean dose of 1.9 and a dose range between 30-120 ug/kg.6, 8,14,15,16

Prostatectomy

Prostatectomy is often associated with major blood loss due to a high content of fibrinolytic activators in the prostate gland. In a double-blind,

placebo-controlled trial with 36 patients undergoing retropubic prostatectomy, patients were randomly assigned to receive placebo or a

single dose of rFVIIa at 20 ug/kg or 40 ug/kg in the early operative phase. More than 50% of the placebo group required red cell transfusion while

none in the rFVIIa required any transfusion.17

Surgery

There are reports of successful use of rFVIIa in controlling hemorrhage following general and cardiac surgery as well as some suggesting that it is

not always effective.18,19,20.

In a trial on spinal surgery, it was reported that there were no statistically significant differences in mortality, serious adverse events or

thromboembolic adverse events between patients who were treated with

30μg/kg, 60μg/kg and 120μg/kg and those treated with placebo.21 After adjusting for factors (duration of surgery, number of vertebral segments

fused and estimated blood volume); the volume and percentage of estimated blood volume lost, total transfusion volumes, mean number of

allogenic blood products transfused and number of RBC units transfused in spinal surgery were statistically significantly lower for all three dosages of

rFVIIa relative to placebo. 21

A meta-analysis of 5 clinical trials that included 298 patients undergoing cardiac surgery using rFVIIa porphylactically or for refractory bleeding

showed a non-significant reduction in the rate of surgical re-exploration.22

Gill et al. reported in their study involving 172 patients that patients receiving rFVIIa for bleeding in post cardiac surgery had significantly fewer

re-operations and significantly less transfusion of allogenic blood and blood products. However, these results must be interpreted cautiously

because the trial is underpowered.23

Thrombocytopenia There are several reports showing variable success with the use of rFVIIa in patients with thrombocytopenia and uncontrolled bleeding.24,25 Only one

24 | P a g e

randomized placebo-controlled study looked at bleeding complications in 100 thrombocytopenic patients following bone marrow transplantation.

Bleedings in these patients were triggered by aplasia, septicemia and graft-versus-host disease. The most common were gastrointestinal hemorrhage

and hemorrhagic cystitis. The results showed that there was no overall effect of rFVIIa administration at doses of 40, 80 or 160 ug/kg 6 hourly for

36 hours.26

Trauma In a randomized, placebo-controlled double-blind trial of 301 trauma

patients, treatment with rFVIIa at doses of 200 ug/kg initially followed by 100 ug/kg, 1 and 3 hours later showed a reduced requirement for red cell transfusion but no reduction in overall mortality.27 The risk of ARDS alone

in patients with blunt trauma was statistically significantly reduced compared to placebo. 27

There are other several reports on the successful use of rFVIIa in patients

with extensive trauma and uncontrolled hemorrhage while there were no response in some. Patients with acidosis and profound shock were less

likely to respond.3

Guideline for the use of rFVIIa

1. Use of rFVIIa in non-haemophilic patients and any decision to use rFVIIa rests exclusively with the prescribing clinicians.

2. Appropriate medical and surgical interventions should be carried out to

reduce the magnitude of critical bleeding before initiating administration of rFVIIa.

3. RFVIIa should only be used where the clinician considers the benefit

outweighs the risk of thrombosis.

4. The algorithm provided here serves as a guide only. Adherence to this guideline is encourage but not mandatory.

5. Following administration of rFVIIa, all patients should be monitored for

signs of improvement and adverse events.

6. The prescribing clinican should report all off-label use of rFVIIa to the rFVIIa Registry in Managing Critical Bleeds in Non-Haemophilia Patients

through completion of the relevant data collection form.

25 | P a g e

Algorithm for use of rFVIIa 28, 29

Control of bleeding source with surgery or

embolisation

Massive

Haemorrhage

- Consider rFVIIa - Discuss with on-call Consultant in-charge - Fill up registry form for off-label use of rFVIIa

Administer rFVIIa (Single bolus over 3-5mins – Dose as per

institution practice)



Re-administer rFVIIa

[PPH: Consider hysterectomy if bleeding

persists after 2 doses of rFVIIa]

Consider after 30-60mins

- Control of bleeding source with surgery or embolisation

- Blood components therapy

- Reversal of any anticoagulation

[PPH: Uterine massage/compression, uterotonic agents]

Attempt to correct:

Hct to > 24%



pH ≥ 7.2


despite surgical control Bleeding

Stopped

Attempt to correct:

Hct to > 24%



pH ≥ 7.2

Bleeding

Stopped

26 | P a g e

References:

1. Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Hemost Thromb 2006;vol 32, suppl 1

2. NovoSeven Approved Package Insert (Malaysia), 2008

3. Martinowitz U, Michaelson M. Guidelines for the use of recombinant

activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost

2005;3:640-648

4. Negrier C, Lienhart A. Overall experience with NovoSeven. Blood Coagul Fibrinolysis 2000;11(suppl 1)

5. Abshire T, Kenet G. Recombinant VIIa: review of efficacy, dosing

regimens and safety in patients with congenital or acquired factor VIII or IX inhibitors. J Haemost Thromb 2004;2:899-909

6. Roberts HR, Monroe DM, White GC. The use of recombinant factor

VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-3864

7. Sobieszczyk S, Breborowicz G, Platicanov V, et al. Recombinant factor

VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol 2006;85:1239-1247

8. Franchini M, Manzato F, Salvagno GL, et al. Potential role of

recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systemic

review. Blood Coagul Fibrinolysis 2007:18:589-593

9. Mayer SA, Brun NC, Begtrup K, et al. Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage. N Engl J Med 2005;352:777-

785

10. Broderick JP, Brott TG, Duldner JE, Tomsick T, et al. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24:987-993

11. Mayer SA et al. Can a subset of Intracerebral Hemorrhage Patients

Benefit from Hemostatic Therapy with Recombinant Activated Factor VII? Stroke 2009;40:833-840.

12. Caldwell SH, Chang C, Macik BG. Recombinant activated factor VIIa

as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 2004;39:592-598

27 | P a g e

13. Hendriks HG, Meijer K, de Wolf JT et al. Reduced transfusion requirements by recombinant factor VIIa in orthotropic liver

transplantation: a pilot study. Transplantation 2001;71:402-405

14. Segal S, Shemesh IY, Blumenthal R, et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa) Arch

Gynecol Obstet 2003;268:266-267

15. Bouma SL, Bolte CA, van Geijn PH. Use of recombinant activated factor VII in massive postpartum haemorrhage. Eu J Obs Gyn Repr

Biol 2008;137:172-177

16. Ahonen J, Jokela R. Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 2005; 94:592-595

17. Friederich PW, Henry CP, Messelink EJ, et al. Effect of recombinant

activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-

controlled randomized trial. Lancet 2003;361:201-205

18. Dietrich W, Spannagl M. Caveat against the use of recombinant activated factor VII for intractable bleeding in cardiac surgery.

Anesth Anagl 2002;94:1369-70

19. Eikelboom JW, Bird R, Blythe D, et al. Recombinant activated factor VII for the treatment of life-threatening hemorrhage. Blood Coagul

Fibrinolysis 2003;14:713-717

20. Tanaka KA, Waly AA, Cooper WA. Treatment of excessive bleeding in Jehovah’s witness patients after cardiac surgery with recombinant

factor VIIa (NovoSeven). Anesthesiology 2003; 98:1513-1515

21. Pohar SL, Tsakonas E, Murphy G et al. Recombinant activated factor VII in treatment of hemorrhage unrelated to haemophilia. The

Cochrane Database of Systematic Reviews, 2009;4

22. Zangrillo A et al. Recombinant Activated Favtor VII in Cardiac Surgery: A Meta-analysis. J Cardiothor Vasc Anesth 2009;23:34040

23. Gill R, Herbertson M, Vuylsteke A. Et al. Safety and efficacy of recombinant activated factor VII. A randomized placebo-controlled

trial in the setting of bleeding after cardiac surgery. Circulation. 2009; 120: 21-27

24. Goodnough LT. Experiences with human recombinant factor VIIa in

patients with thrombocytopenia. Semin Hematol 2004;41:25-29

28 | P a g e

25. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2000;83:634-635

26. Pihusch M, Bacigalupo A, Szer J, et al. Recombinant activated factor

VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 2005;1935-1944

27. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as

adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized, placebo-controlled, double-blind

clinical trials. J Trauma 2005; 59:8-15

28. Vincen JL, Rossaint R, Riou B, Ozier Y, Zideman D and Spahn DR, Recommendations on the use of recombinant activated factor VII as

an adjunctive treatment for massive bleeding – a European perspective. Critical Care 2006, 10:R120

29. Welsh A, McLintock C, Gatt S, Somerset D, Popham P and Ogle R,

Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage, Australian and New Zealand Journal of

Obstetrics and Gynaecology 2008; 48; 12-16

29 | P a g e

GUIDELINES FOR OUTPATIENT TREATMENT OF CHRONIC ASTHMA DEPARTMENT OF MEDICINE HOSPITAL USM

CLASSIFICATION BY SEVERITY1 CLASSIFY SEVERITY

Clinical Feature Before Treatment

Symptoms Nocturnal Symptoms

FEV1 or PEF

STEP 4 Severe

Persistent

Continuous Limited physical activity

Frequent ≤ 60% predicted Variability > 30%

STEP 3 Moderate Persistent

Daily attack affect

activity

> 1 time a week 60-80% predicted

Variability > 30%

STEP 2 Mild

Persistent

> 1 time a week but < 1 time a day

> 2 times a month

≥ 80% predicted Variability 20-

30%

STEP 1 Intermittent

< 1 time a week Asymptomatic

and normal PEF between attacks

≤ 2 times a month

≥ 80% predicted Variability < 20%

TREATMENT

STEP 1- Salbutamol Inhaler as required

STEP 2- Move to step 2 if symptoms as above or failure of step 1

Does the patient has:

Allergic rhinitis?

Definite aspirin allergy?

Exercise induced asthma?

Yes

No

T. Montelukast 10 mg daily2

Salbutamol inhaler as required

Budesonide MDI/Turbuhaler 100-800ug BD

Beclomethasone MDI 50-500 ug BD/TDS

Ciclesonide MDI 160 ug OD/BD

Salbutamol MDI as required

Start steroid at high dose, taper down later1

30 | P a g e

STEP 3- Move to step 3 if symptoms as above or failure of step 2

STEP 4 – Move to step 4 if step 3 fails

Treatment options:

Formoterol/ Budesonide

4.5/160Turbuhaler (Symbicort®) 1 inh BD

or

Salmeterol/ Fluticasone 50/250 Accuhaler

(Seretide®) 1 inhalation BD


Consider Symbicort® if patient is educated

because

• the dose can be adjusted according

to the patients need i.e. 1 inhalation

BD when symptomatic and 1

inhalation daily if stable3

• Symbicort® may be used as rescue

medication

Treatment options:

Formoterol/ Budesonide

4.5/160Turbuhaler (Symbicort®) 1 inh BD

or

Salmeterol/ Fluticasone 50/250 Accuhaler

(Seretide®) 1 inhalation BD


Plus

Montelukast 10 mg daily

KIV

Theophyline SR 250 mg BD

Still symptomatic

Add

Prednisolone 5-10 mg OD

31 | P a g e

Please note:

• Do reversibility test if diagnosis of asthma is questionable

• Do spirometry as baseline before starting any treatment

• Do spirometry before any change of treatment regime

• Discuss with chest physician before starting daily prednisolone

References:

1. Global Initiative For Asthma 2002. www.ginaasthma.com 2. Mastalertz L, et al. Clin Exp Allergyu 2002 Sep;32(9):1360-5

3. Aalbers R, et al. Curr Med Res Opin 2004;20:225-240 Prepared by:

Dr. Che Wan Aminud-din Hashim

Respiratory Physician Department of Medicine

Version 1 Nov 2006

http://www.ginaasthma.com/

32 | P a g e

GUIDELINES FOR USING INFLUENZA VACCINE

Indication:

Patients with the following criteria:-

1. Moderate to severe Chronic Obstructive Pulmonary Disease (Defined by GOLD guideline, HUSM guideline)

2. Asthma with recurrent exacerbation due to flu / URTI 3. Moderate to severe bronchiectasis with recurrent exacerbation 4. Any other chronic lung disease eg. Post-tuberculosis infection,

insterstitial lung disease, etc with recurrent secondary infection.

Management Plan:

Influenza vaccine will be administered as yearly basis.

Prepared by:

Dr. Che Wan Aminud-din b Hashim Repiratory Physician

HUSM

33 | P a g e

FLOW CHART PENGGUNAAN DRUG UNTUK RAWATAN ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

• METHYLPHENIDATE IR (IMMEDIATE RELEASE)

• METHYLPHENIDATE SR (SLOW RELEASE)

• METHYLPHENIDATE LA (LONG ACTING)

• METHYLPHENIDATE (EXTENDED RELEASE) OR CONCERTA

• ATOMOXETINE (STRATERA)

Pesakit dirujuk ke klinik

Diagnosa ADHD

Disediakan oleh: Dr Mohd Jamil Yaacob,

Klinik Psikiatri Kanak-kanak & Remaja. 12 Mac 2012

‘Pure ADHD’ ‘ADHD with comorbidities’

Umur di atas 6 tahun Umur di bawah 6 tahun

IR Methylphenidate (dly-tds)

Methylphenidate (dly-bd)

Methylphenidate LA (single dose)

Concerta (single dose)

Behavior modification

Adult ADHD

Epilepsy

Tics

Gilles de la

Tourette

Complicated

Pervasive SR

Development

Disorders

Severe untoward

events due to

methylphenidate

Atomoxetine (Stratera)

34 | P a g e

Lampiran A

Departmental policy on the use of antipsychotics* and non-standard drugs

1. Since olanzapine and quetiapine are currently available as original products which are expensive; please evaluate the cost-effectiveness

of the treatment when prescribing these drugs as a first line in the management of patients with schizophrenia; especially in

unproductive and chronic patients. 2. The use of expensive drugs such as olanzapine and quetiapine in

poor compliance patients are also discouraged. Typical antipsychotics combined with depot preparation should be strongly

considered. 3. Any patient treated with a new non-standard drug (not in the formulary), it is the responsibility of the drug company to supply the

drug till the patient completed treatment. In such situation the department cannot guarantee that the new drug would be

approved as a standard drug in the formulary.

*Note: this policy may be not relevant any more in future if olanzapine and quetiapine are supplied as generic products.

35 | P a g e

ALGORITHM FOR MEDICATIONS OF SCHIZOPHRENIA

36 | P a g e

37 | P a g e

ACUTE TREATMENT OF MANIA

38 | P a g e

ACUTE TREATMENT OF BIPOLAR DEPRESSION

39 | P a g e

PSYCOPHARMACOLOGICAL TREATMENT ALGORITHM FOR GENERALUIZED ANXIETY DISORDER (GAD)

40 | P a g e

ALGORITHM (2) FOR THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE DISORDER (MDD)

41 | P a g e

ALGORITHM FOR MANAGEMENT OF DEMENTIA

42 | P a g e

ALZHEIMER’S DISEASE TREATMENT STRATEGY

Mild to moderate cases

a) F.D.A. Approval drugs (cholinestherase inhibitors)

b) Use Supported by Clinical Trials

Moderate to severe cases

a) NMDA. Antagonist- Memantine 10-20mg/day

b) Combination of cholinestherase inhibitors + N.M.D.A. Antagonist

1) Donepezil 5-10mg/day

2) Rivastigmine 6-12mg/day

3) Galantamine 16-24mg/day

1) Seligeline 5mg BD.

2) Vit. E 2000I.U./day

43 | P a g e

PARKINSON DISEASE

Last update: February 2012

1 Consider Surgical Treatment

Deep Brain Stimulation

Very advanced motor

Complications of Levodopa Therapy

Severe Symptoms-Motor

Complications of L. Dopa

Moderate motor symptoms

interfering with activities

Early stage with minimal symptoms-

sign

1 Add on Dopamine Receptor

agonist and reduce dose of

Levodopa

2 Add on COMT Inhibitor Ento

Capone (COMTAN)

3 Starton STALLEVO a

combination of Levodopa-

carbidopa Entocaps

4 Adjunctivies – Amantadine Anti-

Cholinergics

1 Add small titrating dose of

Levodopa- dopa de carboxylase

Inhibitor Combination

(L-Dopa-Carbidopa) – Madopar

(L-Dopa-Benzeraside)-Sinement

1 Defer use of Levodopa if age below

60

2 Seligeline

3 Amantadine

4 Dopamine Receptor Agonists

Ropinerol

Pramipexol

Peribedil

5 Anti-cholinergics

44 | P a g e

FLOW CHART FOR TREATMENT HEPATITIS B IN TREATMENT NAÏVE PATIENTS

HBSAg positive

HBeAg status

Positive HBeAg Negative HBeAg

Is ALT Elevated Is ALT Elevated

End points of treatment 1. ALT Normalisation

2. HBeAg Seroconversion/ HBeAntibody 3. HBVDNA (PCR) suppression x 2 undetected 6 months apart (less than

300 copies/ml x 2)

YES

ALT less

2x normal

ALT more than

2x normal

NO YES

NO

ALT less 2x

normal

ALT more than

2x normal

Oral therapy 18 months (minimum)

First choice:

1. Lamivudine 100 mg OD 2. Entecavir 0.5 mg OD 3. Telbivudine 600 mg OD

Second choice:

1. Interferon Alpha (injection)

Liver Biopsy

Ishak Score >2.0

HBVDNA (PCR)

Quantitative more than

100,000 copies/ml

Oral therapy

Minimum duration 2

years

Liver Biopsy

Ishak Score >2.0

HBVDNA (PCR)

Quantitative more

than 10,000 copies/ml

No treatment.

Monitor ALT

every 1-3

months.

45 | P a g e

FLOW CHART OF CHRONIC VIRAL HEPATITIS B PRE CORE MUTANT HBEAG NEGATIVE

HBSAg POSITIVE MORE THAN 6 MONTHS

LIVER ENZYME ALT > 2 × NORMAL

HBVDNA (PCR) QUANTITATIVE HBVDNA > 10,000 COPIES/ML

LIVER BIOPSY

HPE BIOPSY SCORE > 2 ISHAK SCORE

THERAPY FOR MINIMUM 18 MONTHS 1. LAMIVUDINE 100 MG OD 2. TELBIVUDINE 600 MG OD

3. ENTECAVIR 0.5 MG OD 4. PEGYLATED INTERFERON 48 WEEKS

HBVDNA (PCR) QUANTITATIVE

MONITORED AT 24, 48, 72 WEEKS OF THERAPY

THERAPY STOPPED AFTER MINIMUM 18 MONTHS IF HBVDNA (PCR) UNDETECTABLE X 2 AT 6 MONTHS APART

(HBVDNA (PCR) LESS THAN 300 COPIES/ML X 2)

Prepared by:

Dr. Amry A. Rahim Physician / Clinical Specialist

Gastroenterology / Hepatology HUSM

January 2012

46 | P a g e

FLOW CHART FOR GENITAL ULCER SYNDROME

Treatment Protocol For Genital Ulcer Syndrome TREATMENT FOR SYPHILIS AND CHANCROID

1ST FIRST CHOICE: IM BenzathinePenicillin 2.4 million units weekly x 2

(once a week x 2 weeks) PLUS

Azythromycin 1.0 gm single oral dose

2nd SECOND CHOICE: IM Benzathine Penicilin 2.4 million units weekly x 2


Cotrimoxazole 2 tablets orally twice daily x 7 days

3rd THIRD CHOICE: IM Benzathine Penicillin 2.4 million units weekly x 2


IM Ceftriaxone 250mg single dose

Note: If patient develops allergic reaction to the 1st dose of IM Benzathine Penicillin, DO

NOT give the second dose.If patient is allergic to Penicillin, use EITHER Doxycycline 100mg orally bd x 15 days OR Erythromycin ES 800 mg bd x 15 days.

Patient complains of GENITAL ULCER or SORE

Take history and examine

INVESTIGATIONS NEEDED:-

1. Dark ground microscopy for syphilis (IF AVAILABLE) 2. Gramstain for haemophilus ducreyi 3. Tzanck’s smear 4. VDRL, TPHA 5. HIV Ab.

Ulser present? Multiple superficial erosions or vesicular lesions

PRESENT?

• Treat for SYPHILIS and CHANCROID

• Educate for behaviour change

• Partner management

• Follow-up regime For confirmed syphilis

√ 2 weeks for results

√ monthly x 3 visits

√ 3 monthly x 3 visits

√ 3 monthly x 2 visits

• 3 months repeat HIV Ab. And VDRL/TPHA if initial results were negative

• Health Education


• TCA x 2 weeks and review results of inv.

• Genitial herpes management


• TCA x 2 weeks and review results

YES

47 | P a g e

NO

FLOW CHART FOR VAGINAL DISCHARGE SYNDROME

Treatment Protocol For Vaginal Discharge Syndrome (Cervicitis And Vaginitis)

1st FIRST CHOICE: Azithromycin 1 gm single oral dose 2nd SECOND CHOICE: IM Ceftriaxone 250 mg single dose

+

Doxycycline 100 mg bd x 10 –14 days

3rd THIRD CHOICE: IM Ceftriaxone 250 mg single dose +

Erythromycin ES 800 mg bd x 10 – 14 days

PLUS

Metronidazole 2 gm STAT

PLUS Nystatin pessaries 100,000 units daily x 14 days On follow-up: If no improvement or

not effective to continue Metronidazole 400 mg bd x 7 days OR TREATMENT FOR VAGINITIS ONLY

Patient complains of VAGINAL DISCHARGE

Take history and do physical examination

INVESTIGATION NEEDED:-

• Vaginal swab √ Wet mount for trichomonas vaginalis

√ Gram stain for candidia albicans and clue cells

• Cervical swab √ Gram stain for gonococci and pus cells

√ Culture for gonococci ( using Amies charcoal transport media )

• VDRL, TPHA, and HIV ab.

Refer to NEAREST Hospital Patient has LOWER

ABDOMINAL PAIN?

RISK ASSESSMENT

• Partner has symptoms OR

• Risk factor positive

• Treat for VAGINITIS


• Follow up for 2 weeks for results

• Treat for CERVICITIS and Vaginitis



• Follow- up ---2 weeks for result 3 months to repeat VDRL, TPHA & HIV Ab,

IF INITIAL TEST WERE NEGATIVE

RISK FACTORS

1. Less than 21 years old 2. Single 3. Recent partner ( less than 3

monts)

4. Multiple partners

Treatment for Vaginal Discharge Syndrome ( Cervicitis)

Treatment for Vaginal Discharge Syndrome ( Cervicitis)

YES

NO

YES

48 | P a g e

Discharge

PRESENT?

Traetment for CHLAMYDIA

FLOW CHART FOR URETHRAL DISCHARGE SYNDROME IN MEN

Treatment Protocol for Urethral Discharge Syndrome

1st CHOICE: Azithromycin 1gm orally single dose

2nd CHOICE: IM Ceftriaxone 250mg single dose +

Erythromycin ES800mg orally bd x 10-14 days

3rd CHOICE: IM Ceftriaxone 250mg single dose

+ Erythromycin ES 800mg orally bd x 10-14 days

IM Spectinomycin 2gm STAT

+

Doxycycline 100mg orally bd x 10-14 days

OR IM Spectinomycin 2gm STAT +Erythromycin ES 800 mg orally bd x 10-14 days

Patient complains of Urethal

Discharge/Dysuria or irritation

Take history and examine (milk URETHRA

if necessary)

INVESTIGATIONS NEEDED:-

- Urethral smear √ Gram stain for gonococci & pus cells

√ Culture for gonococci (use AMIE’S

charcoal transport media)

- 2 glass urine test

- VDRL,TPHA & HIV Ab

1. Do 2 glass test

2. result POSITIVE? ULCER PRESENT?

• Treat for GONORRHEA and CHLAMYDIA



• Follow-up √ Two weeks for result

√ Three months to repeat

VDRL, TPHA & HIV Ab.

REFER TO

Appropriate

flow chart

Health Education

Follow-up for 2 weeks

No

No

No

Yes Yes

Yes

Treatment for Gonorhea and Chlamvdia

If Patient is allergic to penicillin and azithromycin is not available

49 | P a g e

OUTPATIENT TREATMENT OF CAP

TREATMENT PLAN

YES

YES

NO

PRIMARY CARE OF EMERGENCY DEPT

VISIT Patient presents w/ symptoms suggestive of

community-acquired pneumonia (CAP)

DIAGNOSIS

Does history, physical

Exam & chest x-ray

confirm CAP ?

SITE OF CARE

DECISION

Does patient have any of

the core adverse prognistic

factors?

ALTERNATIVE

DIAGNOSIS

Treat patient appropriately

NO

Yes, 2 core

adverse prognostic

factors are present

No core adverse

prognostic factors

are present

EVALUATION

Does patient have

preexisting adverse

prognostic factors?

CLINICAL DECISION

Should patient be admitted to hospital?

Base decision on clinical judgement,

additional adverse prognostic factors,

the patient’s social circumstances &

patient preferences

OUTPATIENT TREATMENT

Non-pharmacological

• Patient education ➢ Avoid smoking ➢ Adequate hydration &

nutrition

Pharmacotherapy

• Symptomatic therapy ➢ Analgesics for pleuritic

pain

• Antibiotics therapy

NO

Yes, 1 core adverse prognostic

factors are present

HOSPITAL

ADMISSION

YES

50 | P a g e

TREATMENT PLAN (CONT’D)

EMPIRIC OUTPATIENT CAP

ANTIBIOTIC THERAPY

EMPIRIC ORAL ANTIBIOTICS

Local epidemiologic patterns need to be considered to target the antimicrobial therapy against the likely pathogens

Previously healthy individual

Any one of the following :

• High-dose Amoxycillin

• Doxycycline

• Macrolide – Erythromycin ➢ Preferred agent in many guidelines

Comorbidity is present (DM, renal insufficiency, CHF, alcohol abuse, COPD)


• Advanced macrolide - Azithromycin

• Beta-lactam or beta lactam-beta-lactamase inhibitor

• Quinolone Patient has multiple medical condirions , has COPD & received antibiotics or oral steriods in the last 3 months or any other risk factors for Gram –ve organisms

• Macrolide (Azithromycin) + beta lactam or beta-lactam (beta – lactamase inhibitor)

• Quinolone (alone) Suspected aspiration pneumonia


• Beta-lactam, beta-lactamase inhibitor w/ or w/o macrolide (Azithromycin)

• (Clindamycin or metronidazole w/ quinolone)

FOLLOW UP • Follow up will depend on initial severity assessment

• Recommended follow up in 48-72 hr

• If patient fails to improve consider the following : ➢ Chest X-ray ➢ Hospital admission

• Possible reasons for failure to improve ➢ Host factors associated w/ a delayed response ➢ Inadequate antimicrobial selection (eg. Resistant organism or bacteria not covered by initial antibiotic therapy) ➢ Metastatic infections (eg. Meningitis, endocarditis, empysema etc) ➢ Noninfections illness

51 | P a g e

FLOW CHART OF USING SULPERAZONE IN ICU

ICU Patient

Ventilated/NonVentilated

Nosocomial Infection

Acinetobacter Non Acinetobacter

Non-Drug Multi Resistance

Multi-Drug Resistance (MDR)

Quinolones or

3rd Generation or

4th Generation or

Carbapename

Sulperazone Unasyn

±Aminoglycoside

±Aminoglycoside

Responding

Non-Responding Within 24-48 Hr or Suspicious of MDR

Continue Treatment

52 | P a g e

GUIDELINES FOR USING NOVOMIX 30 FLEXPEN HOSPITAL UNIVERSITI SAINS MALAYSIA

PRE-MIXED INSULIN

Mixtard 30 Penfill NovoMix 30

FlexPen

OAD’s

failures

OAD’s failure

1. elderly

2. hypoglycaemic prone

3. fasting (ramadhan) or puasa

sunat)

Patients on Mixtard (switch

to)

1. frequent hypoglycaemia

2. poor control

3. post prandial

hyperglyacemic

4. fasting (ramadhan) or puasa

sunat)

OAD Failure

PRE-MIX INSULIN

(eg: Mixtard, Humulin 30/70)

NovoMix30

1. Hypoglycemia 2. Poor glycemic control

53 | P a g e

FLOWCHART FOR USE OF GLUCOPHAGE XR

Type 2 Diabetes Mellitus

Metformin (immediate release) BID/TID

Poor compliance or Gastro-intestinal side-effects

Metformin (extended release) (Glucophage XR) once daily

54 | P a g e

FLOWCHART FOR USE OF INSULIN DETEMIR

Insulin requiring diabetes

mellitus

NPH insulin

Hypoglycemia

Insulin Detemir/Glargine

Last update: February 2012

55 | P a g e

ALGORITHM FOR THE MANAGEMENT OF POSTMENOPAUSAL OSTEOPOROSIS

T score: T score: T score:

≥ -1 -2.5 ≤ -2.5

Monitor

Patients with

incidental low trauma fracture

Patients with risk

factor but no fracture

General measures:

- Calcium intake (B)

- Physical activity (B)

In the elderly:

- Vitamin D + calcium (A)

- Prevention of falls (B)

BMD measurement

Clinical Assessment

Treatment options:

-Strontium ranelate

-Bishosphonate (A)

-SERMs (A) -Activated vitamin D

(A)

-Calcitonin (A)

-rPTH**(A)

Treatment options:

-Strontium ranelate -SERMs (A)

-Bishosphonate (A)

-Activated vitamin D (A)

If multiple risk factor present (C)

Treatment options:

-Strontium ranelate

-SERMs (A)

-Alendronate (A) - HRT (A)

Reassess BMD yearly (C)

Follow up with BMD if available

OSTEOPENIA*

OSTEOPOROSIS OSTEOPOROSIS (BMD if available)

NORMAL

NO YES

If BMD deteriorates

Reassess

with BMD

after 2

years (A)

56 | P a g e

ZOLENDRONIC ACID PRESCRIPTION FLOW CHART

FLOW CHART FOR USING IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML), PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Bone Metastasis –Confirmed By Bone Scan

Primary By:

1) Breast Carcinoma

2) Nasopharyngeal Carcinoma

3) Lung Carcinoma (NSCLC)

4) Prostate Carcinoma

1st Line

IV Zolendronic Acid 4 mg

over 15 minutes every 4

weeks for 6 months.

Palliative Intension.

To stop and reduce bone

metastases/damage

especially when bone

involvement is wide

spread

+/- Hypercalcaemia

Severe pain. Scale > 7/10

2nd Line

IV Zolendronic Acid 4

mg over 15 minutes

every 4 weeks for 6

months

Further pain +/-

Hypercalcaemia

1st Line

IV Pamidronate 90 mg

Over 2 hours every 4/52

For 6 months

Severe Hypercalcaemia Mild To Moderate Pain

Symptoms of Pain

57 | P a g e

Patients with Ph+CML (all phases)

Begin imatinib at 400mg daily

Assess response at 3, 6, 12, 18 months as

per European Leukemia Net guidelines

Good response

Suboptimal

response

Poor / No

response

Continue imatinib

400 mg daily Increase imatinib to

600-800 mg daily

Stop imatinib

Consider alternative

treatment

Good response

Poor / No

response

Continue imatinib

600-800 mg daily

Stop imatinib

Consider alternative

treatment

NB

1. Chronic phase CML patients responding to imatinib should continue treatment indefinitely until disease progression (expected rate of

progression 1-5 %/year)

2. In accelerated, blast phase CML and Ph+ALL imatinib is usually used as induction +/- chemotherapy prior to more definitive treatment like

stem cell with an anticipated duration of imatinib use of 4-8 weeks.

58 | P a g e

Lampiran1 Dr. Shamsul Kamaruljan

ARCOXIA PRESCRIPTION FLOW CHART

*Prescription: Maximum only for 3/52 Dose: 60mg, 90mg and 120mg (Depends on severity of the pain and condition of the pain)

1st line:

T. Celebrex 200-400mg dly

T. Meloxicam 7.5mg bd

T. Tramadol 50-100mg tds

Oral opiods e.g. T. DF118,

Oral morphine

1st line:

NSAIDS e.g Voltaren, Mefenamic

acid, Ibuprofen

History of Gastritis

2nd line:

T. Celebrex 200-400mg dly

T. Meloxicam 7.5mg bd

Oral opiods e.g. T.DF118, Oral

morphine

2nd line:

T. Arcoxia 60-120mg dly

T. Oxycontin 10-40mg bd

3rd line:



Yes No

Pain not

relieved

Pain not

relieved

Pain not

relieved

Acute/chronic pain

59 | P a g e

Lampiran 2 Setelah diubahsuai oleh Jabatan Ortopedik

OUTPATIENT PAIN PRESCRIPTION FLOW CHART

*COX2 Prescription for acute pain: Maximun only for 3/52 Arcoxia Dose: 60mg (OA), 90mg (RA) and 120mg (Acute pain e.g. gouty

arthritis) (Depends on severity of the pain and condition of the pain)

3rd line is same in both pathways

1st line:

AC: T. Celebrex 200-400mg dly

AC Gouty arthritis : T Arcoxia

120mg daily

CHR: T. Meloxicam 7.5mg dly

T Celebrex 200mg dly

1st line:

AC: Voltaren, Mefenamic acid,

Ibuprofen

CHR: Feldene, Neprosyn

Acute/chronic pain

History of Gastritis

2nd line:

AC: Oral opiods e.g. T.DF118,

T. Arcoxia 120mg dly

CHR: T. Celebrex 200 dly

T. Meloxicam 7.5mg dly

2nd line:

Oral opiods e.g. T.DF118,


3rd line:

Oral morphine


3rd line:

Oral morphine


Yes No

Pain not

relieved

Pain not

relieved

Pain not

relieved

AC – acute

CHR - chronic

60 | P a g e

FLOWCHART OF PATIENTS DIAGNOSED WITH BACTERIAL CONJUNCTIVITIS

Bacterial Conjunctivitis

1st line:

Gutt. Chloramphenicol

Perform Culture and

Sensitivity test Not resolved

2nd line:

Gutt. Ciprofloxacin (Ciloxan)

Not resolved

3rd line:

Gutt. Moxifloxacin (Vigamox)

61 | P a g e

FLOWCHART OF PATIENTS DIAGNOSED WITH BACTERIAL KERATITIS

Bacterial Keratitis

1st line:

Gutt. Ciprofloxacin (Ciloxan)

Perform Cornea

Scrapping/ Culture Not resolved and Sensitivity test

2nd line:

Gutt. Moxifloxacin (Vigamox)

62 | P a g e

FLOWCHART OF PATIENTS REQUIRING PRE AND POST CATARACT SURGERY ANTIBIOTIC PROPHYLAXIS

Cataract Surgery

Prophylaxis

Pre–op prophylaxis:

• Gutt. Moxifloxacin 0.5 % (Vigamox) 1 drop every 15 minutes 1 hour prior to surgery.

• 5 % Povidone – iodine ( 1 drop ) on the ocular surface.

Intra-cameral injection:

• 1mg in 0.1 mL cefuroxime* or

• 0.1 mL Gutt. Moxifloxacin 0.5% (Vigamox)1

- at the end of surgery

*Dilution is required as standard cefuroxime injection is 100 mg/mL.

Reference: 1) CRG Espiritu et. al. Safety of Prophylactic Intracameral Moxifloxacin 0.5%

Opthalmic Solution in Cataract Surgery Patients. J Cataract Refract Surg 2007: 33: 63-68

Post–op prophylaxis:

• Gutt. Moxifloxacin 0.5% (Vigamox) 4 times daily for 1 month.

63 | P a g e

FLOW CHART FOR USING OLOPATADINE 0.1%

i. Kegunaan ubat tersebut adalah untuk rawatan kes “Allergic conjunctivitis” terutama “Vernal kerato conjunctivitis” di

kalangan kanak-kanak dan remaja.

“Flow chart” penggunaan kedua-dua drug bagi membezakan kes-kes

tersebut seperti berikut;

Last update: January 2012

Ubat titis Olopatadine

Pesakit “Allergic conjunctivitis”

terutama “Vernal kerato

conjunctivitis”

Pesakit

64 | P a g e

TREATMENT ALGORITHM OF ALLERGIC RHINITIS (AR)

Intermittent Symptoms Persistent Symptoms

Xyzal * (Bachert C et al. J. Allergy Clin. Immunol 2004; 114: 838-844) The XPERT, Xyzal in Persistent Allergic Rhinitis Trial – Published RCT data.

Indication approved by FDA / DCA.

Diagnosis of AR

Allergen Avoidance

Drug Therapy (Antihistamines)

Moderate - Severe

Moderate - Severe

Mild Mild

Xyzal Xyzal * Xyzal Xyzal *

1st & 2nd generation antihistaminics

1st & 2nd generation antihistaminics (No clinical data available to support

this indication

65 | P a g e

FLOW CHART OF THALASSAEMIA PATIENT WITH IRON OVERLOAD

DIAGNOSIS OF THALASSAEMIA ON REGULAR BLOOD TRANSFUSION

REGULAR 3-4 MONTHLY FOLLOW-UP IN PAEDIATRIC HAEMATOLOGY

CLINIC

REGULAR 3-4 WEEKLY FOLLOW-UP IN THALASSAEMIA DAY CARE UNIT

FOR BLOOD TRANSFUSION

3 MONTHLY MONITORING SERUM FERRITIN LEVEL

EVIDENCE OF IRON OVERLOAD, SERUM FERRITIN > 1000 MCG/L

INTRODUCE TO SUBCUTANEOUS DESFERAL (deferoxamine) WITH

TRAINING AND MONITORING

ASSESSMENT OF COMPLIANCE TO DESFERAL (Growth, Se Ferritin, yearly

echo of heart)

POOR COMPLIANCE GOOD COMPLIANCE TO DESFERAL TO DESFERAL

Se Ferritin Se Ferritin

< 2500mcg/L > 2500mcg/L CONTINUE DESFERAL

DEFERASIROX DEFERIPRONE

66 | P a g e

INTERFERON BETA-1B FLOWCHART

Multiple Sclerosis

1) Remitting and Relapsing type.

2) Clinically Isolated syndrome with MRI evidence of

multiple plaques.

DIAGNOSIS ESTABLISHED AS PER Mc DONALD CRITERIA

TREAT THE ACUTE EPISODE WITH I.V METHYL PREDNISOLONE

THEN CONSIDER THE THERAPEUTIC OPTION OF STARTING BETA-INTERFERON THERAPY.

(Beta interferon is the only evidence based treatment for the above condition, to reduce the risk of relapses and slow down the disease

progression).

67 | P a g e

GUIDELINE OF PAIN MANAGEMENT

In deciding on the selection of drug in managing pain, prescriber is advised to follow the

step-ladder guideline provided by Malaysian Ministry of Health (1) as follows:

STEP-LADDER FOR ACUTE PAIN MANAGEMENT

SEVERE UNCONTROLLED

7-10 To refer to APS for: PCA or Epidaral or

Others MODERATE Regular

Tramadol 50-100mg QID

OR Morphine 5-10

mg 4hrly SC/IV

+PCM 1gm QID

+NSAID/ COX2 inhibitor

PRN Morphine

4hriy oral/SC/IV Oxynorm 5-10 mg 4-6 hrly

4-6

MILD Regular Tramadol 50-TDS/

QID +Oral

PCM 1gm QID

+NSAID/ COX2

inhibitor

PRN Additional tramadol 50-100 mg(max

400 mg/day)

DF118 30-60 mg 6-

8hly

1-3

Regular

No medication

or PCM 1gm 6hrly

PRN PCM&/or NSAID/ COX2

inhibitor

Notes 1. Dihydrocodeine (DF118) may be used as an alternative to Tramadol

2. In NBM patients oral drugs may be replaced by:

a) Tramadol SC or IV

b) PCM rectal

c) Diclofenac rectal or Parecoxib IV

▪ NSAIDs should be used with caution in patients with asthma, thrombocytopenia,

coagulopathies, and renal, hepatic or cardiac impairment.

▪ NSAIDs are contraindicated in patients with hypovolemia, active peptic

ulceration and those with a history of hypersensitivity, e.g. wheezing to aspirin or

any other NSAIDs.

▪ In the elderly (over 65 years),avoid or consider using a lower dose of NSAID

▪ Those at risk of Gl problems or with symptoms (epigastric pain) may be

"bufferedwith Proton Pump Inhibitors.

▪ For those with severe pain, use SC or IV morphine and titrate to comfort

(seeappendix 5 Morphine Pain Protocol)

▪ Used of Oxynorm only for APS team

▪ Refer to APS team for uncontrollable severe pain

2. The following are the NSAIDs product available in Hospital USM

DRUG STRENGTH CRITERIA OF USE

ACETYLSALICYLIC ACID

Tab. 300 mg

NAPROXEN Tab. 250 mg

68 | P a g e

PARECOXIB Inj 40 mg Anaesthesiologist Only. Restricted for ICU/ HDU

and OT only

CELECOXIB Cap 200 mg & Cap 400 mg

Follow Guideline On Prescription

Of COX-2 Inhibitors

DICLOFENAC SODIUM

Tab 50 mg, Inj 75 mg, Supp 12.5 mg & Supp

100mg.

ETORICOXIB Tab 60 mg, 90 mg & 120 mg

Follow Guideline On Prescription

Of COX-2 Inhibitors

IBUPROFEN Tab 200 mg

INDOMETHACIN Cap 25 mg, Inj 1 mg

MEFENAMIC ACID Cap 250 mg

MELOXICAM Tab 7.5 mg Follow the Chronic Pain Management Protocol.

3. Guideline On Prescription Of COX-2 Inhibitors

The following guideline are supposed to be followed by standard practice of both prescribers and pharmacist in HUSM:

3.1. Indication for usage of Cox-2 inhibitor are: 3.1.1 Patient with gastritis or having risk of getting gastritis

3.1.2. Oral analgesia for post-operative pain 3.2. Initiation of Celecoxib/Etoricoxib should be done by specialist

3.3. In case of chronic pain, continuation after 6 months has to be endorsed by specialist

3.4. In patient with worsening pain/inadequate analgesia, treating physician should revise analgesia using step-ladder approach in section.1

3.5 Any treatment approach beyond this guideline is tO be decided by expert in the field

4. Recommendation for usage of COX-2 inhibitor in ACUTE PAIN for pa with gastritis or risk of having gastritis (maximum 2 weeks) are:

4.1 Celecoxib 200 me PRN/ Etoricoxib 90 mg PRN +/- Tab. Paracetamol l gm PRN

▪ Tab. Paracetamol PRN 20 tabs/ 14 days

▪ Celecoxib/Etoricoxib PRN = 6 caps/14 days

OR

4.2 Celecoxib 200 mg OD/ Etoricoxib 90 mg OD + Tab.Paracetamol 1 g PRN

▪ Celecoxib/ Etoricoxib shall be supplied as prescribed duration

▪ Tab. Paracetamol PRN =20 tabs/ 14 days

OR

4.3 Celecoxib 400 mg OD (maximun 5 days) /Etoricoxib 120 mg OD (maximum 8

days) followed by option 4.1 or 4.25.

5. Recommendation for usage of COX-2 inhibitor in CHRONIC PAIN for patients with gastritis or risk of having gastritis are:

5.1.Tab.Paracetamol 1 g PRN +Celecoxib 200mg PRN/ Etoricoxib 90 mgPRN ▪ Tab.Paracetamol PRN= 40 tabs /month

69 | P a g e

▪ Celecoxib/Etoricoxib PRN= 10 caps/ month

OR 5.2.Celecoxib 200 mg OD/ Etoricoxib 90 mg OD

OR 5.3.Celecoxib 200 mg OD/ Etoricoxib 90 mg OD+Tab.Paracetamol 1 g PRN

▪ Celecoxib/ Etoricoxib shall be supplied as prescribed duration

▪ Tab.Paracetamol PRN = 40 tabs/ month

References: 1. Pain Management Handbook, (2013). Ministry of Health Malaysia

MOH/P/IPAK/257.12 (HB), MOH Portal: www.moh.gov.my

2. World Health Organization, (2009). WHO's Pain Relief Ladder.

www.who.int/cancer/palliativelpainladder/enl

3. Department of Pharmacy, Hospital USM. www.dformulary.h.usm.my

Committee members Prof. Dr. Abdul Razak Sulaiman Puan Noor Aini Abu Samah

Prof. Dr. Shamsul Kamalrujan Hassan Puan Hajah Norita Abdul Hamid @ Jusoh

Prof. Madya Dr. Abdul Nawfar Sadagatullah Puan Nur Aida Murni Mamamad

Prof. Madya Dr Rosediani Muhamad Pn. Noor Shufiza lbrahim

Prof. Madya Dr Syed Hassan Syed Abd Aziz Pn. Nik Azira Nik Ab. Ghani

Dr Mohd Hashairi Fauzi

Dr Wan Syamimee Wan Ghazali

Date of approval by Pharmacy and Therapeutic committee: 28 March 2017

http://www.moh.gov.my/http://www.who.int/cancer/palliativelpainladder/enl

70 | P a g e

GUIDELINE ON THE USE OF GLUCOSAMINE FOR OSTEOARTHRITIS PATIENT FOR USM STAFF (13TH MARCH

2018) PROF DR ABDUL RAZAK SULAIMAN

Members:

Prof Dr Abdul Razak Sulaiman

Prof. Dr Mohd Imran Yusof

Prof Dr Amran Ahmad Sokri

Prof. Madya Dr Tg Muzaffar Tg Mohamad Shihabudin

Prof. Madya Dr Rosediani Muhamad

Prof. Madya Dr Azidah Abdul Kadir

Dr Ismail Munanjat

Dr Norul Badriah Hassan

Dr Shaifuzain Ab Rahman

Puan Norita Abdul Hamid @Jusoh

Puan Nooraini Omar

1. There are still contradicting evidences on the benefit of Glucosamine in osteoarthritis

- Evidences for usage:

o D. Wu et al (2013) in Int J Cli Practice,Glucosamine has benefit as

diseasemodifying drugs if given more than 6 months.

o Cochrane review 2005:-Patented Crystalline Glucosamine sulfate (viatril S)

hasclear benefit over placebo on pain, stiffness and function. Other preparation

of glucosamine has no significant benefit over placebo.

o 0.Bruyere et al Seminars in Arthritis and Rheumatism 45 (2016) S12-S17: -

treatment with pCGS for at least 12 months leads to a reduction in the need for

total joint replacement for at least 5 years following treatment cessation.

o Meta analysis by Black et al: NO different between sachet and capsul as long as

dose of 1500mg/day is taken.

- Evidences against:

o AAOS 2nd edition :AAOS does not recommend using glucosamine and

chondroitin for patient with symptomatic OA of the knee.

o Mc Alindon, 2014 Journal Osteoarthritis and Cartilage :systematic review and

meta-analysis of RCT: given less then three (3) months, it will not be effective -

Usage for pain relief is uncertain.It is not appropriate for disease modification

2. Based on experiece treating the patient and available evidences, the committee conclude

that patient would only get the benefit if it given with proper indication as follows

a. Primary OA at early stage of disease (stage l and Ii).

b. Patented Crystalline Glucosamine sulfate (viatril S ®) at 1500mg/day (either

sachet or capsule)

c. Together with other modality like weight reduction and physiotherapy

d. Not all patients will benefit

3. Therefore recommendations are (algorithm attached):

a. Only to be prescribed by orthopaedic surgeon that know the exact indication and

decision to continue or stop

71 | P a g e

b. Reassessment is to be done at 3 months basis.

c. Patented Crystalline Glucosamine sulfate (viatril S) at 1500mg/day (either

sachet or

d. For patients older than 45 years old as patients younger than that is likely to be

capsule) secondary osteoarthritis

e. Must be in combination with weight reduction and physiotherapy program.

f. One course of treatment is 6 months to one year.

g. Any usage beyond this recommendation is to be decided by the expert in the

field.

*USM only support for 6 months. The continuation of treatment is to be paid by

patients. This is similar to practice by KKM.

Algorithm/diagram: glucosamine usage guidelines for knee OA (USM staff)

1st prescription:

• To confirm diagnosis of knee OA:

1. Clinical ACR criteria

2. Radiological (K-L grading): 2 or 3 only

• 45 years old & above

2

3 months prescription /trials3

Review: response To check

compliance & optimum dose 2,3

-ve +ve

Stop Treatment3 To continue for

another 3/123

Recheck Diagnosis

Other Options:

a. Piascladine

b. Diacerine

C. Chondroitin

If further improvement: recommend use

up to 1 year 1,2

N/B: pt to self-buy3

The use of up to 2 years -surgeon's

discretion 5,6

Recommended for multi-modal

approach in conjunctions with

Glucosamine guidelines:

1. Non-pharma - weight loss

(diet, exercise). Physiotherapy

(strengthening & stretching)

2. Pharma-analgesic

72 | P a g e

HOSPITAL UNI

drug use flow chartsdformulary.h.usm.my/assets/flow_chart_2020v9nov... · 3 | p a g e flow chart...

Documents